GlassScriptPhysician profile
James Jeffery Boyd
NPI 1417057381
$1,379.58
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $256 · 2020: $354 · 2021: $562 · 2022: $159 · 2023: $34.98 · 2024: $13.68.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $48.66.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $48.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $334.73 | 2019-2021 | |
| Janssen Biotech, INC. | $194.17 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $146.15 | 2020-2021 | |
| Teleflex LLC | $128.92 | 2022 | |
| Cook Medical LLC | $110.57 | 2020 | |
| Tolmar Pharmaceuticals, INC. | $99.80 | 2019-2021 | |
| Allergan, INC. | $58.67 | 2020-2021 | |
| Coloplast Corp | $49.56 | 2020-2021 | |
| Acerus Pharmaceuticals Corporation | $45.43 | 2021 | |
| Urovant Sciences INC | $44.28 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $34.98 | 2023 | Gemtesa |
| Boston Scientific Corporation | $33.27 | 2019-2024 | Spaceoar Vue System - 10ml |
| Mission Pharmacal Company | $33.01 | 2020 | |
| Blue Earth Diagnostics | $14.39 | 2022 | |
| Ambu INC. | $14.05 | 2020 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $13.20 | 2021 | |
| Photocure INC | $12.31 | 2021 | |
| Pfizer INC. | $12.09 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Boyd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.